
Cambridge Healthtech Institute’s 13th Annual
Liquid Biopsy
Enabling Precision Oncology for Diagnostic and Drug Development
March 6-7, 2023
Liquid biopsy is a maturing technology for early detection of disease, patient stratification and therapy selection, monitoring response to therapy, and detecting disease recurrence. Cambridge Healthtech Institute’s 13th Annual Liquid
Biopsy meeting will explore the latest technologies in detection and molecular characterization of CTCs, cell-free circulating tumor DNA (cfDNA) and circulating extracellular RNA, exosomes and microvesicles, as well as the applications of liquid biopsy
in diagnostics and drug development.
Coverage will include, but is not limited to:
- Technology update in liquid biopsy detection and characterization
- Cancer screening and early detection
- Liquid biopsy for minimal residual disease detection
- Applications of cell-free DNA and RNA as biomarkers in drug development
- Exosomes and microvesicles as biomarkers
- Predicting immunotherapy response through circulating immune cells
- Liquid biopsy for companion diagnostics
The deadline for priority consideration is July 15, 2022.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation:
For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com
For sponsorship information, please contact:
Jon Stroup
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5483
Email: jstroup@healthtech.com